{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:37:04Z","timestamp":1794487024206,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Advancements in frontline therapies have substantially improved outcomes in newly diagnosed multiple myeloma (NDMM); however, many patients will not achieve deep responses and will relapse. Teclistamab, a BCMA\u00d7CD3 bispecific antibody, in combination with daratumumab, has demonstrated strong efficacy in relapsed\/refractory multiple myeloma versus standard of care as early as first relapse. This ongoing phase 2 GMMG-HD10\/DSMM-XX (MajesTEC-5) study evaluates teclistamab-based regimens in transplant-eligible NDMM. In this prespecified pooled analysis of three cohorts, 49 patients received teclistamab\/daratumumab\/lenalidomide (Tec-DR; arms A and A1) or Tec-DR with bortezomib (Tec-DVR; arm B). Primary endpoints were incidence and severity of adverse events (AEs) and serious AEs; secondary endpoints included overall response rate (ORR), minimal residual disease (MRD) negativity and MRD-negative complete response (CR). The current analysis spans the induction and autologous stem cell transplantation phases until the premaintenance timepoint. Grade 3 or 4 treatment-emergent AEs (TEAEs) occurred in 91.8% (45\/49); most were hematologic (lymphopenia (59.2%; 29\/49), neutropenia (59.2%; 29\/49) and leukopenia (18.4%; 9\/49)). No grade 5 TEAEs were reported. Serious AEs occurred in 55.1% (27\/49); pyrexia (12.2% (6\/49)) was most common. Any-grade and grade 3 or 4 infections occurred in 81.6% (40\/49) and 36.7% (18\/49), respectively, the most common grade 3 or 4 infections being COVID-19 and pneumonia (6.1% (3\/49) each). Cytokine release syndrome occurred in 67.3% (33\/49); all were grade 1 or 2, all resolved and none led to discontinuation of any study treatment. No treatment-related immune effector cell-associated neurotoxicity syndrome (ICANS) events occurred. Across arms, the MRD-negative CR rate was 91.8% (45\/49) by the premaintenance timepoint; the MRD negativity rate was 100% in evaluable samples at postinduction cycle 3 (1\u2009\u00d7\u200910\n                    <jats:sup>\u22125<\/jats:sup>\n                    (46\/46)), cycle 6 (1\u2009\u00d7\u200910\n                    <jats:sup>\u22125<\/jats:sup>\n                    (46\/46) and 1\u2009\u00d7\u200910\n                    <jats:sup>\u22126<\/jats:sup>\n                    (46\/46)) and premaintenance (1\u2009\u00d7\u200910\n                    <jats:sup>\u22125<\/jats:sup>\n                    (40\/40)); the ORR was 100% (49\/49). Total median stem cell yield was 8.1\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    per kg. Data support the feasibility of Tec-D(V)R induction in transplant-eligible NDMM, with a consistent safety profile compared with individual regimen components and notable early MRD negativity rates. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05695508\" ext-link-type=\"uri\">NCT05695508<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04471-x","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:03:32Z","timestamp":1782378212000},"page":"2440-2448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-3234","authenticated-orcid":false,"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-0506","authenticated-orcid":false,"given":"Jan","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Fenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilli","family":"Podola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Brobeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mersi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Arlinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan R.","family":"Bohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-1252","authenticated-orcid":false,"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Schub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-1818","authenticated-orcid":false,"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-2609","authenticated-orcid":false,"given":"Florian","family":"Bassermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caline","family":"Sakabedoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ershova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-5132","authenticated-orcid":false,"given":"Bas D.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7803-0814","authenticated-orcid":false,"given":"Hans","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the GMMG-HD10\/DSMM-XX (MajesTEC-5) investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"4471_CR1","doi-asserted-by":"publisher","first-page":"7502","DOI":"10.1200\/JCO.2024.42.16_suppl.7502","volume":"42","author":"P Rodr\u00edguez-Otero","year":"2024","unstructured":"Rodr\u00edguez-Otero, P. et al. Daratumumab (DARA) + bortezomib\/lenalidomide\/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial. J. Clin. Oncol. 42, 7502 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4471_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld, P. et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 390, 301\u2013313 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4471_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren, O. et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Blood 144, 359\u2013367 (2024).","journal-title":"Blood"},{"key":"4471_CR4","unstructured":"TECVAYLI (teclistamab-cqyv). Package insert (Janssen Biotech, 2026)."},{"key":"4471_CR5","unstructured":"TECVAYLI (teclistamab). Summary of product characteristics (Janssen Biologics BV, 2022)."},{"key":"4471_CR6","doi-asserted-by":"crossref","unstructured":"Garfall, A. L. et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 42, 7540 (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"4471_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva, D. et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood 144, 615\u2013628 (2024).","journal-title":"Blood"},{"key":"4471_CR8","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie, B. et al. Curing myeloma at last: defining criteria and providing the evidence. Blood 124, 3043\u20133051 (2014).","journal-title":"Blood"},{"key":"4471_CR9","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","volume":"26","author":"KA Frerichs","year":"2020","unstructured":"Frerichs, K. A. et al. Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. Clin. Cancer Res. 26, 2203\u20132215 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4471_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1158\/1535-7163.MCT-22-0498","volume":"22","author":"J Li","year":"2023","unstructured":"Li, J., Slaga, D., Johnston, J. & Junttila, T. T. IMiDs augment CD3-bispecific antibody\u2013induced CD8+ T-cell cytotoxicity and expansion by enhancing IL2 production. Mol. Cancer Ther. 22, 659\u2013666 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"4471_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/CMAR.S4555","volume":"1","author":"JP Laubach","year":"2009","unstructured":"Laubach, J. P. et al. Bortezomib in the management of multiple myeloma. Cancer Manag. Res. 1, 107\u2013117 (2009).","journal-title":"Cancer Manag. Res."},{"key":"4471_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","volume":"394","author":"LJ Costa","year":"2026","unstructured":"Costa, L. J. et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 394, 739\u2013752 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4471_CR13","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117, 4691\u20134695 (2011).","journal-title":"Blood"},{"key":"4471_CR14","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/leu.2015.290","volume":"29","author":"BG Durie","year":"2015","unstructured":"Durie, B. G., Miguel, J. F., Blade, J. & Rajkumar, S. V. Clarification of the definition of complete response in multiple myeloma. Leukemia 29, 2416\u20132417 (2015).","journal-title":"Leukemia"},{"key":"4471_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"4471_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4471_CR17","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","volume":"39","author":"T Facon","year":"2025","unstructured":"Facon, T. et al. Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia 39, 942\u2013950 (2025).","journal-title":"Leukemia"},{"key":"4471_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136, 936\u2013945 (2020).","journal-title":"Blood"},{"key":"4471_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/blood-2024-200181","volume":"144","author":"A D\u2019Souza","year":"2024","unstructured":"D\u2019Souza, A. et al. Teclistamab, daratumumab, and pomalidomide in patients with relapsed\/refractory multiple myeloma: results from the MajesTEC-2 cohort A and TRIMM-2 studies. Blood 144, 495 (2024).","journal-title":"Blood"},{"key":"4471_CR20","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero, P. et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 25, e205\u2013e216 (2024).","journal-title":"Lancet Oncol."},{"key":"4471_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2025-367","volume":"146","author":"S Manier","year":"2025","unstructured":"Manier, S. et al. A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort a. Blood 146, 367 (2025).","journal-title":"Blood"},{"key":"4471_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani, S. Z. et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398, 665\u2013674 (2021).","journal-title":"Lancet"},{"key":"4471_CR23","doi-asserted-by":"publisher","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima, D. et al. Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transplant. Cell. Ther. 30, 308.e1\u2013308.e13 (2024).","journal-title":"Transplant. Cell. Ther."},{"key":"4471_CR24","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1182\/bloodadvances.2024012724","volume":"8","author":"IS Hamadeh","year":"2024","unstructured":"Hamadeh, I. S. et al. Patterns of CRS with teclistamab in relapsed\/refractory multiple myeloma with or without prior T-cell redirection therapy. Blood Adv. 8, 3038\u20133044 (2024).","journal-title":"Blood Adv."},{"key":"4471_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"CR Tan","year":"2025","unstructured":"Tan, C. R. et al. Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J. 15, 53 (2025).","journal-title":"Blood Cancer J."},{"key":"4471_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood.2024026814","volume":"145","author":"S Harding","year":"2025","unstructured":"Harding, S. & Mikhael, J. Down with dex! Blood 145, 3\u20134 (2025).","journal-title":"Blood"},{"key":"4471_CR27","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood.2024026212","volume":"144","author":"H Lee","year":"2024","unstructured":"Lee, H. et al. Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood 144, 2637\u20132651 (2024).","journal-title":"Blood"},{"key":"4471_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/JCO-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai, E. K. et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J. Clin. Oncol. 43, 1279\u20131288 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4471_CR29","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi, N. C. et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 4, 5988\u20135999 (2020).","journal-title":"Blood Adv."},{"key":"4471_CR30","first-page":"564","volume":"16","author":"S Gandolfi","year":"2018","unstructured":"Gandolfi, S. et al. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin. Adv. Hematol. Oncol. 16, 564\u2013574 (2018).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"4471_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood-2024-200300","volume":"114","author":"D Vishwamitra","year":"2024","unstructured":"Vishwamitra, D. et al. Pharmacodynamic signatures and correlatives of response in patients with relapsed\/refractory multiple myeloma treated with talquetamab or teclistamab plus daratumumab and pomalidomide. Blood 114, 594 (2024).","journal-title":"Blood"},{"key":"4471_CR32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik, J. et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384\u2013394 (2016).","journal-title":"Blood"},{"key":"4471_CR33","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos, M. A. et al. EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat. Rev. Clin. Oncol. 22, 680\u2013700 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4471_CR34","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 380, 2104\u20132115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4471_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blade","year":"2022","unstructured":"Blade, J. et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 12, 45 (2022).","journal-title":"Blood Cancer J."},{"key":"4471_CR36","doi-asserted-by":"publisher","first-page":"LBA-6","DOI":"10.1182\/blood-2025-LBA-6","volume":"146","author":"M-V Mateos","year":"2025","unstructured":"Mateos, M.-V. et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator\u2019s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd\/DVd) in patients with relapsed refractory multiple myeloma (RRMM): results of MajesTEC-3. Blood 146, LBA-6 (2025).","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1038\/s41591-026-04551-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04471-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04471-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04471-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:02:08Z","timestamp":1784210528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04471-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4471"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04471-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04551-y","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04551-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.R. is currently employed by Heidelberg University Hospital and reports research funding from Bristol Myers Squibb, Janssen and Heidelberg Pharma; consultancy for Bristol Myers Squibb, Amgen, GlaxoSmithKline, Janssen, Sanofi, Pfizer, AbbVie, Oncopeptides and Takeda; honoraria from Bristol Myers Squibb, Amgen, GlaxoSmithKline, Janssen, Sanofi, Pfizer, AbbVie and Oncopeptides; membership on an entity\u2019s board of directors or advisory committees for Janssen, Amgen, Bristol Myers Squibb, Sanofi, AbbVie and GlaxoSmithKline; and travel expenses from Bristol Myers Squibb, Amgen, Janssen, Sanofi, AbbVie and Oncopeptides. N.W. is funded by the Advanced Medical Scientist Program of Heidelberg University, Faculty of Medicine, and reports research funding from The Binding Site, Sanofi-Aventis and Bristol Myers Squibb\/Celgene; honoraria from Sanofi-Aventis; and membership on an entity\u2019s board of directors or advisory committees for Sanofi-Aventis and GlaxoSmithKline. K.M.K. is currently employed by University Hospital Wurzburg and reports honoraria from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanofi, Takeda and Stemline Therapeutics and consultancy for AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanofi, Takeda and Stemline Therapeutics. J. Kr\u00f6nke is currently employed by Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin and reports consultancy for Janssen, Takeda, AbbVie, Jazz Pharmaceuticals, Sanofi, AstraZeneca and Pfizer; honoraria from Janssen, Takeda, AbbVie, Jazz Pharmaceuticals, Sanofi, AstraZeneca and Pfizer; and speakers bureau for Janssen, Takeda, AbbVie, Jazz Pharmaceuticals, Sanofi, AstraZeneca and Pfizer. R.F. reports honoraria from Pfizer, Sanofi, Takeda, Janssen, Bristol Myers Squibb\/Celgene and Amgen and travel expenses from Janssen, GlaxoSmithKline and Bristol Myers Squibb\/Celgene. K.W. reports consultancy for Bristol Myers Squibb\/Celgene, Sanofi, GlaxoSmithKline, Pfizer, Menarini, Janssen, Adaptive Biotechnologies, Amgen, Roche, BeiGene, Oncopeptides, Karyopharma, Takeda and Regeneron; honoraria from Bristol Myers Squibb\/Celgene, Sanofi, GlaxoSmithKline, Pfizer, Menarini, Janssen, Adaptive Biotechnologies, Amgen, Roche, AstraZeneca, BeiGene, Oncopeptides, Karyopharma, Novartis, Stemline Therapeutics and Takeda; and research grants to institution from Bristol Myers Squibb\/Celgene, Sanofi, GlaxoSmithKline, Janssen, Amgen and AbbVie. L.P. is employed by the University Clinic Heidelberg. L.P. has no conflicts of interest to report. U.B. has no conflicts of interest to report. A.B. has no conflicts of interest to report. J.M. reports serving in an advisory role for Johnson & Johnson and Pfizer and receiving honoraria from Johnson & Johnson, Sanofi, Pfizer and Skyline Dx. S.H. has no conflicts of interest to report. R.A. has no conflicts of interest to report. M. Hundemer reports research funding from Novartis, Janssen, Sanofi, Bristol Myers Squibb\/Celgene, Alexion and Roche; membership on an entity\u2019s board of directors or advisory committees for Becton Dickinson and BeiGene; and travel expenses from BeiGene and Bristol Myers Squibb\/Celgene. S.R.B. reports honoraria and consultation fees from Johnson & Johnson, Pfizer, Sanofi, Takeda and GlaxoSmithKline. E.K.M. reports serving in a consulting or advisory role for Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, Pfizer, Sanofi, Stemline Therapeutics and Takeda; honoraria from Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, Pfizer, Sanofi, Stemline Therapeutics and Takeda; research funding from Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda; and travel accommodations and expenses from Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline Therapeutics and Takeda. N.S. reports honoraria from Bristol Myers Squibb\/Celgene and Janssen. J.W. reports honoraria from GlaxoSmithKline, Menarini-Stemline Therapeutics, Pfizer, AbbVie, Sanofi, Bristol Myers Squibb, Oncopeptides and Janssen; and research support from Bristol Myers Squibb. F.B. reports honoraria from Bristol Myers Squibb\/Celgene and Janssen. C.M.-T. is employed by the University Hospital Heidelberg, and the department receives funding for clinical trials from multiple entities, including Johnson & Johnson. C.H. is employed by, and may own stock in, Johnson & Johnson. C.S. is employed by, and may own stock in, Johnson & Johnson. J. Khan is employed by, and may own stock in, Johnson & Johnson. E.E. is employed by, and may own stock in, Johnson & Johnson. B.D.K. is employed by, and may own stock in, Johnson & Johnson. M.E. reports consultancy for Janssen, Bristol Myers Squibb, Sanofi, Takeda and Pfizer; research funding from Janssen; and honoraria from Janssen, Bristol Myers Squibb, Sanofi and Pfizer. M. H\u00e4nel reports honoraria from the Falk Foundation, Kite Pharma, Gilead Sciences, Bristol Myers Squibb, Sobi and Novartis; consultancy for Kite Pharma, Pfizer, Roche, Bristol Myers Squibb, Jazz Pharmaceuticals, GlaxoSmithKline, Takeda, Janssen, Bayer Vital, Sobi, Incyte, Sanofi-Aventis and Amgen; and membership on an entity\u2019s board of directors or advisory committees for Kite Pharma, Pfizer, Roche, Bristol Myers Squibb, Jazz Pharmaceuticals, GlaxoSmithKline, Takeda, Janssen, Bayer Vital, Sobi, Sanofi-Aventis and Amgen. H.S. reports honoraria from Janssen, Bristol Myers Squibb GmbH & Co. KG, Amgen, AbbVie, Stemline Therapeutics, Oncopeptides, AstraZeneca, Sanofi, Genzyme, GlaxoSmithKline, Pfizer and Roche; reports serving in a consulting or advisory role for Pfizer, Janssen Oncology, Sanofi, Oncopeptides, GlaxoSmithKline, Amgen, AbbVie, Bristol Myers Squibb\/Celgene, Roche, Genzyme, Stemline Therapeutics and AstraZeneca; and travel accommodations and expenses from Amgen, Bristol Myers Squibb GmbH & Co. KG, Janssen, Pfizer, Stemline Therapeutics and Sanofi. R.T. is currently employed by University Hospital Carl Gustav Carus and reports consultancy for Janssen, Bristol Myers Squibb and Amgen; research funding from Janssen; and honoraria from Janssen, Bristol Myers Squibb, Takeda, GlaxoSmithKline, Gilead Sciences, Amgen, Sanofi, Stemline Therapeutics, Oncopeptides and AbbVie. H.G. reports honoraria from Amgen, Bristol Myers Squibb, Chugai, Sanofi, GlaxoSmithKline, Janssen, Novartis and Pfizer; membership on an entity\u2019s board of directors or advisory committees for Amgen, Bristol Myers Squibb, Adaptive Biotechnologies, Sanofi and Janssen; travel expenses from Amgen, Bristol Myers Squibb, Sanofi, GlaxoSmithKline, Janssen, Novartis and Pfizer; grants and\/or provision of investigational medicinal product from Chugai, Sanofi, Array Biopharma\/Pfizer, the Dietmar Hopp Foundation, Bristol Myers Squibb\/Celgene, Janssen, Johns Hopkins University and Mundipharma GmbH; and research funding from Celgene, Amgen, Bristol Myers Squibb, Sanofi, GlaxoSmithKline, Takeda, GlycoMimetics, Heidelberg Pharma, F. Hoffmann-La Roche, Janssen, Incyte Corporation, Karyopharm, Merck, Millennium Pharmaceuticals, Molecular Partners, MorphoSys AG, Novartis and Pfizer. H.E. reports honoraria from Bristol Myers Squibb, Sanofi, Bristol Myers Squibb\/Celgene, Janssen, Amgen, Novartis and Takeda; membership on an entity\u2019s board of directors or advisory committees for Bristol Myers Squibb\/Celgene, Janssen, Amgen, Novartis and Takeda; and research funding from Bristol Myers Squibb\/Celgene, Janssen, Amgen and Novartis. L.R. reports honoraria from Janssen, Pfizer, GlaxoSmithKline, Bristol Myers Squibb and Amgen and research funding from Skyline Dx and Bristol Myers Squibb.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}